Epithelial growth factor receptor status in primary and recurrent ovarian cancer.
Standard
Epithelial growth factor receptor status in primary and recurrent ovarian cancer. / Stadlmann, Sylvia; Gueth, Uwe; Reiser, Ulrich; Diener, Pierre-Andre; Zeimet, Alain Gustave; Wight, Edward; Mirlacher, Martina; Sauter, Guido; Mihatsch, Michael J; Singer, Gad.
in: MODERN PATHOL, Jahrgang 19, Nr. 4, 4, 2006, S. 607-610.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Epithelial growth factor receptor status in primary and recurrent ovarian cancer.
AU - Stadlmann, Sylvia
AU - Gueth, Uwe
AU - Reiser, Ulrich
AU - Diener, Pierre-Andre
AU - Zeimet, Alain Gustave
AU - Wight, Edward
AU - Mirlacher, Martina
AU - Sauter, Guido
AU - Mihatsch, Michael J
AU - Singer, Gad
PY - 2006
Y1 - 2006
N2 - Success of epidermal growth factor receptor (EGFR) targeting agents in different cancer types is related to EGFR gene mutations and/or copy number gains. We investigated the EGFR gene status and protein expression by DNA mutational analysis, fluorescence in situ hybridization (FISH), and immunohistochemistry in tumor tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas. The patients were classified into six groups with ascending EGFR gene copy numbers. EGFR amplification and high polysomy (FISH+) was present in a significant fraction of the primary (20%) and recurrent (22%) ovarian carcinomas. On mutational analysis, only one tumor with a silent EGFR mutation was observed, and this was the only carcinoma with high-level amplification. EGFR protein immunoexpression was seen in 28% of primary and 33% of recurrent carcinomas and correlated to amplification in the primary tumors (P = 0.003). In recurrent carcinoma, moderate and strong EGFR expression was associated with amplification (P = 0.034). These molecular events potentially have impact on the responsiveness to EGFR targeting agents in ovarian cancer.
AB - Success of epidermal growth factor receptor (EGFR) targeting agents in different cancer types is related to EGFR gene mutations and/or copy number gains. We investigated the EGFR gene status and protein expression by DNA mutational analysis, fluorescence in situ hybridization (FISH), and immunohistochemistry in tumor tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas. The patients were classified into six groups with ascending EGFR gene copy numbers. EGFR amplification and high polysomy (FISH+) was present in a significant fraction of the primary (20%) and recurrent (22%) ovarian carcinomas. On mutational analysis, only one tumor with a silent EGFR mutation was observed, and this was the only carcinoma with high-level amplification. EGFR protein immunoexpression was seen in 28% of primary and 33% of recurrent carcinomas and correlated to amplification in the primary tumors (P = 0.003). In recurrent carcinoma, moderate and strong EGFR expression was associated with amplification (P = 0.034). These molecular events potentially have impact on the responsiveness to EGFR targeting agents in ovarian cancer.
M3 - SCORING: Zeitschriftenaufsatz
VL - 19
SP - 607
EP - 610
JO - MODERN PATHOL
JF - MODERN PATHOL
SN - 0893-3952
IS - 4
M1 - 4
ER -
